Stock Pick

  • Omeros Rallies On COVID-19 Study Results: What You Should Know

    Omeros Rallies On COVID-19 Study Results: What You Should KnowOmeros Corporation (NASDAQ: OMER) shares were galloping higher Monday after the biopharma announced results from a compassionate use study of its lead investigational human monoclonal antibody.What Happened: Seattle-based Omeros said its narsoplimab, when administered to six COVID-19 patients with Acute Respiratory Distress Syndrome who initially required mechanical ventilation, led to recovery, survival and discharge from the hospital.Mannan-binding lectin-associated serine protease-2, or MASP-2, binds the nucleocapsid protein of SARS-CoV-2 — the virus responsible for COVID-19 — resulting in complement activation and lung injury.Narsoplimab targets MASP-2, alleviating symptoms of COVID-19, including ARDS and thrombotic events, according to Omeros. Narsoplimab is being evaluated as a treatment option for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HSCT-TMA.Rolling BLA submission is underway for the indication, Omeros said.The study of narsoplimab in COVID-19 was initiated following a request from treating physicians at the Papa Giovanni XXIII Hospital in Bergamo, Italy, the company said.The uniformly successful outcomes of the study are impressive, Alessandro Rambaldi, head of the department of hematology and oncology at Papa Giovanni, said in a statement. Rambaldi also served as the lead investigator for the HSCT-TMA trial. "Also of importance in this terribly sick population studied, the drug was well-tolerated, showing no adverse effects," Rambaldi said. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.What's Next: Omeros said a manuscript detailing the results of the study has been accepted for publication in the peer-reviewed journal Immunobiology.OMER Price Action: At last check, Omeros shares were surging higher by 49.89% to $21.18. Related Links:The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic * Why BofA Has The Street's Highest Nvidia Price Target Ahead Of The Q2 Print * Why iPhone 12 Will Be Another 'Defining Chapter' In Apple's Growth Story(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2XOPyQD

  • How Much Did Ideanomics'(NASDAQ:IDEX) Shareholders Earn From Share Price Movements Over The Last Five Years?

    How Much Did Ideanomics'(NASDAQ:IDEX) Shareholders Earn From Share Price Movements Over The Last Five Years?It is doubtless a positive to see that the Ideanomics, Inc. (NASDAQ:IDEX) share price has gained some 272% in the last…

    from Yahoo Finance https://ift.tt/3kvPBuu

  • Stephens Puts Trade Desk On Hold After 2Q Revenue

    Stephens Puts Trade Desk On Hold After 2Q RevenueStephens downgraded Trade Desk to Hold from Buy citing the stock's high valuation. The advertising tech company on Aug. 6 posted 2Q earnings that beat analysts' expectations. Shares rose 2.6% on Friday.Stephens analyst Kyle Evans stated that the recent run-up in Trade Desk (TTD) stock in comparison to the valuation and mixed 2Q revenue performance led to the downgrade. The analyst maintained a price target of $470 (4.7% downside potential).Trade Desk's 2Q earnings of $0.92 per share beat analysts’ estimates of $0.17. Its revenues of $139.4 million surpassed Street estimates of $134.9 million. Overall though 2Q sales and earnings declined on a year-over-year basis. (See TTD stock analysis on TipRanks).RBC Capital analyst Mark Mahaney raised Trade Desk's price target to $510 (3.4% upside potential) from $300 but maintained a Hold rating. “Trade Desk saw a large deceleration in growth from Q4 levels but July trends suggested a strong recovery,” Mahaney wrote in a note to investors.Currently, the Street has a cautiously optimistic outlook on the stock. The Moderate Buy analyst consensus is based on 4 Buys versus 6 Holds. Given the year-to-date stock increase of around 90%, the average price target of $465 implies downside potential of about 5.7%.Related News: Wedbush Lifts Apple’s PT To ‘Street High’ ON Semiconductor Quarterly Profit Misses Estimates; Top Analyst Sticks To Buy Barclays Lifts Uber’s PT On Recovery Bet More recent articles from Smarter Analyst: * MGM Spikes 14% As IAC Makes $1B Investment Amid Online Gambling Bet * Marriot Posts Wider-Than-Expected 2Q Loss, Sees 'Gradual Recovery' * FedEx Gains 5% As Bernstein Raises Stock To Buy * Northland Cuts Stamps.com To Hold Despite 2Q Earnings Beat

    from Yahoo Finance https://ift.tt/3abXTms

  • Kodak nosedives after $765M government loan is put on hold

    Kodak nosedives after $765M government loan is put on holdYahoo Finance’s Alexis Keenan joins Zack Guzman to discuss how Kodak shares tanked more than 40% as the government loan is put on pause while allegations of the company are investigated.

    from Yahoo Finance https://ift.tt/2DSoV66

  • 5 Common Forex Trading Mistakes You Want to Avoid

    The great thing about forex trading is that almost anyone with a computer, internet connection and a bit of extra cash can dive in. With that, though, comes those who enter without preparation. That’s when you hear their stories of failing at forex trading and give you a bad taste if thinking of entering. Don’t Read More…

    The post 5 Common Forex Trading Mistakes You Want to Avoid appeared first on Wall Street Survivor.

    source https://blog.wallstreetsurvivor.com/2020/08/10/5-common-forex-trading-mistakes-you-want-to-avoid/

  • Coronavirus update: Kodak federal loan in jeopardy; Gilead seeks approval of remdesivir

    Coronavirus update: Kodak federal loan in jeopardy; Gilead seeks approval of remdesivirTop stories about how the coronavirus pandemic is affecting business around the world.

    from Yahoo Finance https://ift.tt/31HG2jk

  • Tiktok talks with Microsoft unlikely to end in a deal: SCMP Rpt.

    Tiktok talks with Microsoft unlikely to end in a deal: SCMP Rpt.TikTok talks with Microsoft unlikely to end in deal. Yahoo Finance’s On The Move panel shares the details.

    from Yahoo Finance https://ift.tt/2Fc6mL5

  • What Type Of Returns Would Ford Motor’s(NYSE:F) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

    What Type Of Returns Would Ford Motor's(NYSE:F) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Ford Motor Company (NYSE:F) shareholders will doubtless be very grateful to see the share price up 34% in the last…

    from Yahoo Finance https://ift.tt/2CeJVng

  • TikTok talks with Microsoft unlikely to end in deal: SCMP Rpt

    TikTok talks with Microsoft unlikely to end in deal: SCMP RptTikTok will unlikely come to a deal with Microsoft. Yahoo Finance’s On The Move panel shares the details.

    from Yahoo Finance https://ift.tt/2DO8XKn

  • Need To Know: Cree, Inc. (NASDAQ:CREE) Insiders Have Been Buying Shares

    Need To Know: Cree, Inc. (NASDAQ:CREE) Insiders Have Been Buying SharesIt is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be…

    from Yahoo Finance https://ift.tt/3kuywkD